Dardinger v. Anthem Blue Cross & Blue Shield

781 N.E.2d 121, 98 Ohio St. 3d 77
CourtOhio Supreme Court
DecidedDecember 20, 2002
DocketNo. 2001-1222
StatusPublished
Cited by83 cases

This text of 781 N.E.2d 121 (Dardinger v. Anthem Blue Cross & Blue Shield) is published on Counsel Stack Legal Research, covering Ohio Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dardinger v. Anthem Blue Cross & Blue Shield, 781 N.E.2d 121, 98 Ohio St. 3d 77 (Ohio 2002).

Opinions

Pfeifer, J.

Factual Background

{¶ 1} There are two factual portions of this case relevant to our determination. The first set of facts is that which gives rise to the claims of the plaintiffs for breach of contract, bad faith, and punitive damages. The second set of facts is relevant in determining whether defendant Anthem Insurance Companies, Inc., waived a possible defense.

The Claim

{¶ 2} The plaintiff-appellant in this case is Robert Dardinger, executor of the estate of his wife, Esther Dardinger. There are two defendants-appellees. The first is Community Insurance Company, an Ohio corporation that does business under the trade name Anthem Blue Cross and Blue Shield (“Anthem”). Anthem is a wholly owned subsidiary of the second defendant-appellee, Anthem Insurance Companies, Inc. (“AICI”), which was once known as Associated Insurance Companies, Inc.

[78]*78{¶ 3} The plaintiff and the defendants are before this court because of what happened to Esther Dardinger as she fought her battle against brain cancer in 1997. Esther died on November 6, 1997, at age 49. Her last days were spent in great pain as the cancerous tumors in her brain took their final, brutal toll. The plaintiff claims that the way defendants handled Esther’s chemotherapy needlessly shortened her life and caused her last days to be more painful than they should have been.

Pre-July 1997

{¶ 4} In October 1996, Esther was diagnosed with metastatic brain tumors. The cancer had spread from her breast. Esther underwent radiation therapy, which stabilized, but did not shrink, the tumors. In March 1997, Dr. Herbert Newton, the director of neuro-oncology at the James Cancer Hospital and Solove Research Institute at the Ohio State University (“OSU”), began treating her. Dr. Newton recommended that Esther begin intra-arterial chemotherapy (“IAC”) in order to shrink the tumors. The neuro-oncology tumor board at OSU agreed with Dr. Newton’s assessment and recommendation.

{¶ 5} IAC delivers chemotherapy to brain tumors by means of an arterial catheter threaded through whichever artery is feeding the area of the brain where the tumor is located and into the brain. The purpose of IAC is to deliver substantially higher doses of chemotherapy directly to the affected tumors without subjecting the rest of the body’s organs to the drugs’ toxicity.

{¶ 6} Beginning in April 1997, Esther began a course of IAC. She had IAC treatments in early April and early May. The IAC treatments seemed to be working for Esther, shrinking the tumors, relieving pain, and alleviating symptoms. An MRI taken on June 5,1997, after the first two treatments, showed that the largest of the three tumors had shrunk significantly, a second had also shrunk, and a third had nearly disappeared. She underwent another round of IAC on June 10 and 11, 1997, and, again, tolerated the procedure well. Dr. Newton scheduled a fourth procedure for June 30 and July 1,1997.

{¶ 7} It is the fourth procedure and its aftermath that are the focus of this case. Anthem decided, after approving and paying for the first three treatments of a planned 12-treatment program, that it would no longer pay for Esther’s IAC treatments. Although Anthem’s decision to halt payment for treatments was reported to Dr. Newton just before the fourth treatment, he and the Dardingers decided to move forward with that treatment, assuming that Anthem’s denial was merely a glitch in the system. Esther received her fourth IAC treatment on June 30 and July 1. Newton planned to appeal Anthem’s denial through Anthem’s administrative process.

[79]*79{¶ 8} Anthem believes that the only glitch in its system was in allowing the first three IAC treatments to proceed. Anthem places the blame for that decision on its medical director for the Columbus area, Dr. Stanley Borg. Before Esther’s first treatment, Anthem had requested the opinion of a professional consultant and board-certified oncologist, Dr. John Pancoast. However, Dr. Pancoast was out of town and would not return before Esther’s first IAC treatment.

{¶ 9} With Dr. Pancoast unavailable, Dr. Borg exercised his own authority and preapproved payment for one IAC treatment. After its own Columbus Area Medical Director precertified the first treatment, two of Anthem’s nurses precertified payment for the next two IAC administrations.

{¶ 10} By the time of the fourth treatment, Dr. Pancoast had become available to review Dr. Newton’s request for precertification of Esther’s fourth IAC cycle. An Anthem precertification nurse sent Dr. Newton’s June 24, 1997 request for the treatment to Dr. Pancoast for his opinion. According to Dr. Pancoast’s records, he spent ten minutes reviewing the request. His records also reflected that he had approved IAC for another of Dr. Newton’s brain tumor patients (that patient’s tumor was primary, not metastatic) just before his denial of Esther’s IAC. Dr. Pancoast felt that Dr. Newton had no scientific literature to show that the treatment was nonexperimental in the treatment of brain metastases. Dr. Pancoast recommended that Anthem decline payment for the treatment.

{¶ 11} On June 27, 1997, Anthem informed Dr. Newton that payment for the requested IAC would be denied because the treatment was experimental. Anthem’s reasoning for denying payment for the procedure changed over time. In a letter sent to Dr. Newton’s office the same day as the phone call, Anthem said that coverage was denied because IAC should be done on an outpatient rather than inpatient basis. In other correspondence, Anthem cited the reasons for its denial as “not meeting medical policy for ‘Off-Label Use of Drugs,’ ” because “the services do not meet the criteria of our medical policy,” and because the drugs had not been approved for the treatment requested.

July

{¶ 12} Upon learning that Anthem had denied coverage, the Dardingers immediately tried to get Anthem to reconsider. On July 2, the Dardingers’ insurance agent from Ohio Benefits Group, Tammy Kornja, spoke with Stephanie Hughes, an Anthem service representative, regarding the denial. Hughes told Kornja that she should have Dr. Newton call Anthem to speak to a physician about the situation. Kornja called Anthem again on July 17 to check on the status of the situation, but Hughes had nothing to report.

[80]*80{¶ 13} Plaintiff, Bob Dardinger, was also trying to get answers from Anthem. On July 7, he called Anthem and talked to Beth Jones, a precertification nurse. While understanding that OSU would be handling the official appeal of Anthem’s decision, Bob called to see what he could do to expedite the situation. He wondered why the treatment that Esther’s doctor said would give her the best chance to survive had been refused by Anthem. He was told to talk to his doctor, that OSU would be handling the appeal, and to wait out the appeals process.

{¶ 14} OSU began preparing for the appeal internally as of July 1, 1997. Mary Ann Slivka, a nurse working with Dr. Newton, wrote a letter to OSU’s Patient Care Resource Management (“PCRM”) Department requesting its assistance on Esther’s appeal. She gave the department background on Esther’s treatment and Anthem’s reasons, as stated in its telephone call of June 27, for denying coverage. She wrote another letter to the PCRM Department on July 7, since Anthem’s letter of denial had stated a different reason — that the service did not require an inpatient admission — than Anthem had given in its original phone call.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Triad Hunter, L.L.C. v. Eagle Natrium, L.L.C.
2024 Ohio 5188 (Ohio Court of Appeals, 2024)
State v. Kraynak
2024 Ohio 1428 (Ohio Court of Appeals, 2024)
Gibson Bros., Inc. v. Oberlin College
2022 Ohio 1079 (Ohio Court of Appeals, 2022)
In re Adoption of C.B.B.G.
2021 Ohio 331 (Ohio Court of Appeals, 2021)
Shields v. Plummer
2020 Ohio 5449 (Ohio Court of Appeals, 2020)
Lakes v. Bath & Body Works, LLC
E.D. California, 2019
Stark Cnty. Park Dist. v. Dickerhoof
2018 Ohio 4319 (Ohio Court of Appeals, 2018)
Phoenix Lighting Group, LLC v. Genlyte Thomas Group, LLC
2018 Ohio 2393 (Ohio Court of Appeals, 2018)
Kassay v. Niederst Mgmt., Ltd.
113 N.E.3d 1038 (Court of Appeals of Ohio, Eighth District, Cuyahoga County, 2018)
Rieger v. Giant Eagle, Inc.
2018 Ohio 1837 (Ohio Court of Appeals, 2018)
AM & JV, LLC v. MyFlori, LLC
107 N.E.3d 125 (Court of Appeals of Ohio, Tenth District, Franklin County, 2018)
Gateway Consultants Group, Inc. v. Premier Physicians Ctrs., Inc.
2017 Ohio 1443 (Ohio Court of Appeals, 2017)
Sundquist v. Bank of America, N.A. (In re Sundquist)
566 B.R. 563 (E.D. California, 2017)
Sivit v. Village Green of Beachwood, L.P.
2016 Ohio 2940 (Ohio Court of Appeals, 2016)
Whetstone v. Binner (Slip Opinion)
2016 Ohio 1006 (Ohio Supreme Court, 2016)
Sivit v. Village Green of Beachwood, L.P.
35 N.E.3d 508 (Ohio Supreme Court, 2015)
Burns v. Adams
2014 Ohio 1917 (Ohio Court of Appeals, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
781 N.E.2d 121, 98 Ohio St. 3d 77, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dardinger-v-anthem-blue-cross-blue-shield-ohio-2002.